Pulmonary toxicity of inhaled aerosolized prostacyclin therapy - an observational study

Anaesthesia and Intensive Care

Volumn 28, Issue 2, 2000, Pages 161-166

  Van Heerden, P V ^a,b   Caterina, P ^b,c   Filion, P ^a   Spagnolo, D V ^a   Gibbs, N M ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PathCentre ^*  (Australia)

Author keywords

PROSTAGLANDIN: prostacyclin, inhalational; TOXICITY: pulmonary, prostacyclin

Indexed keywords

ANTITHROMBOCYTIC AGENT; DILUENT; GLYCINE; PROSTACYCLIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHIOLE; CONTROLLED STUDY; HISTOLOGY; INFLAMMATION; LUNG TOXICITY; NONHUMAN; SWINE; TRACHEITIS; ULTRASTRUCTURE;

EID: 0034127165     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0002800206     Document Type: Article

References (40)

1. Silvester W. Prostacyclin in review: its physiology and role in intensive care. Intensive Care World 1997; 15:22-39.
2. Burghuber OC, Silberbauer K, Haber P, Sinzinger H, Elliott M, Leithner C. Pulmonary and antiaggregatory effects of prostacyclin after inhalation and intravenous infusion. Respiration 1984; 45:450-454.
3. 2) on platelet behaviour. Thrombus formation in vivo and bleeding time. Thromb Haemost 1979; 41:425-435.
4. Moncada S, Vane JR. Prostacyclin and blood coagulation. Drugs 1981:21:430-437.
5. Szczeklik A, Gryglewski RJ, Nizankowska E, Nizankowska R, Musial J. Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man. Prostaglandins 1978;16:651-660.
6. Weite M, Zwissler B, Habazettl H, Messmer K. PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur Sug Res 1993; 25:329-340.
7. Bindl L, Fahnenstich H, Peukert U. Aerosolized prostacyclin for pulmonary hypertension in neonates. Arch Dis Child 1994; 71:F214-F216.
8. Haas NA, Schulze-Neick I, Lange PE. Intratracheal prostacyclin for resuscitation in primary pulmonary hypertension. Lancet 1995; 346:643.
9. van Heerden PV, Webb SAR, Hee G, Corkeron M, Thompson WR. Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemia. Anaesth Intensive Care 1996; 24:87-90.
10. Webb SAR, Stott S, van Heerden PV. The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism. Intensive Care Med 1996; 22:353-355.
11. van Heerden PV, BIythe D, Webb SAR. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS - A pilot study. Anaesth Intensive Care 1996; 24:564-568.
12. Walmrath D, Schneider T, Pilch J, Grimminger F, Sceger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993; 342:961-962.
13. Zwissler B, Weite M, Habler O, Kleen M, Messmer K. Effects of inhaled prostacyclin as compared with inhaled nitric oxide in a canine model of pulmonary microembolism and oleic acid edema. J Cardiothorac Vasc Anesth 1995; 9:634-640.
14. Schranz D, Huth R, Wipperman C, Ritzerfeld S, Schmitt F, Oelert H. Nitric oxide and prostacyclin lower suprasystemic pulmonary hypertension after cardiopulmonary bypass. Eur J Pediatr 1993; 152:793-796.
15. Walmrath D, Schneider T, Scherrnuly R, Olschcwski H, Grimminger F, Seegcr W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153:991-996.
16. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:1671-1677.
17. Booke M, Bradford DW, Hinder F, et al. Effects of inhaled nitric oxide and nebulized prostacyclin on hypoxic pulmonary vasoconstriction in anesthetized sheep. Crit Care Med 1996; 24:1841-1848.
18. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten S. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 1998; 114:780-786.
19. Pappert D, Busch T, Gerlach H, Lewandowski K, Radermacher P, Rossaint R. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 1995; 82:1507-1511.
20. Eichelbronner O, Reinelt H, Wiedeck H, Mezody M, Rossaint R, Georgieff M, et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock - different effects on splanchnic oxygnation? Intens Care Med 1996; 22:880-887.
21. van Heerden PV, Power BM, Leonard RC. Re: Delivery of inhaled aerosolised prostacyclin (IAP). Anaesth Intens Care 1996; 24:624-625.
22. Habler O, Kleen M, Zwissler B, et al. Inhalation of prostacyclin (PGI2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs. Intens Care Med 1996; 22:426-433.
23. Habler O, Kleen M, Takenaka S, et al. Eight hours' inhalation of prostacyclin (PGI2) in healthy lambs: effects on tracheal, bronchial, and alveolar morphology. Intensive Care Med 1996; 22:1232-1238.
24. Dianco S, Robuschi M, Grugni A, Ceserani R, Gandolfi C. Effect of prostacyclin on antigen induced immediate bronchoconstriction in asthmatic patients. Prostaglandins Med 1979; 3:39-45.
25. Doyle P, Swart M, Kong A. Inhaled prostacyclin as a selective pulmonary vasodilator. Anaesth Intensive Care 1996; 24: 514-515.
26. Bein T, Pfeifer M, Riegger GAJ, Taeger K. Continuous intraarterial measurement of oxygenation during aerosolized prostacyclin administration in severe respiratory failure. N Engl J Med 1994; 331:335-336.
27. Bein T, Keyl C, Pfeifer M, Metz C. Administration of aerosolized prostacyclin in patients with severe respiratory failure and pulmonary hypertension. Chest 1995; 108:1195.
28. Wetzel RC. Aerosolized prostacyclin. In search of the ideal pulmonary vasodilator. Anesthesiology 1995; 82:1315-1317.
29. Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger VV. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 1995; 151:724-730.
30. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Secger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124:820-824.
31. 2 ae) in patients (p) with pulmonary hypertension (PH) associated with ARDS. Intensive Care Med 1996; 22:5408.
32. Kieler-Jensen N, Milocco I, Kirno K, Houltz E, Ricksten S. Effects of prostacyclin on myocardial hemodynamics and metabolism after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 1996; 10:741-747.
33. Haraldsson A, Kieler-Jensen N, Ricksten S. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: A pharmacodynamic study. J Cardiothorac Vasc Anesth 1996;10:864-868.
34. Santak B, Schreiber M, Kuen P, Lang D, Radermachcr P. Prostacyclin aerosol in an infant with pulmonary hypertension. Eur J Pediatr 1995; 154:233-235.
35. Bein T, Metz C, Keyl C, Sendtner E, Pfeifer M. Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulizing system. J Cardiovasc Pharmacol 1996; 27:583-586.
36. 2): new aspects of an old substance in the treatment of critically ill patients. Intensive Care Med 1997; 3:146-158.
37. Royston D. Inhalation agents for pulmonary hypertension. Lancet 1993; 342:941-942.
38. Soditt V, Aring C, Groneck P. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn. Intensive Care Med 1997; 23:1275-1278.
39. McGinn PV, Black AJR. Use of nebulised prostacyclin to ascertain reversibility of secondary pulmonary hypertension. Aust N Z J Med 1996; 26:234-235.
40. Mikhail G, Gibbs SR, Richardson M, et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997; 18:1499-1504.